Processa Pharmaceuticals Stock Performance
| PCSA Stock | USD 3.14 0.05 1.57% |
The company holds a Beta of 1.57, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Processa Pharmaceuticals will likely underperform. At this point, Processa Pharmaceuticals has a negative expected return of -0.4%. Please make sure to check Processa Pharmaceuticals' accumulation distribution, and the relationship between the potential upside and day median price , to decide if Processa Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Processa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
Five Day Return (9.77) | Year To Date Return 7.17 | Ten Year Return (99.78) | All Time Return (99.96) |
Last Split Factor 1:25 | Dividend Date 2019-12-23 | Last Split Date 2025-12-17 |
1 | Is Processa Pharmaceuticals Inc. stock ready for a breakout - Market Growth Report Reliable Price Breakout Alerts - newser.com | 11/03/2025 |
2 | Acquisition by Patrick Lin of 3 shares of Processa Pharmaceuticals subject to Rule 16b-3 | 11/12/2025 |
3 | Maxim Group Maintains Processa Pharmaceuticals With Hold Rating - | 11/20/2025 |
4 | Acquisition by Neal James R of 300000 shares of Processa Pharmaceuticals at 0.198 subject to Rule 16b-3 | 12/10/2025 |
5 | Processa Pharmaceuticals to effect 1-for-25 reverse stock split - marketscreener.com | 12/15/2025 |
6 | PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study | 12/18/2025 |
7 | Why did Processa Pharmaceuticals stock surge 160 percent today - MSN | 12/29/2025 |
8 | Acquisition by Wendy Guy of 150000 shares of Processa Pharmaceuticals at 0.198 subject to Rule 16b-3 | 12/30/2025 |
9 | Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - The Progress Index | 01/08/2026 |
10 | Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference | 01/12/2026 |
11 | Acquisition by Pannu Geraldine of 300000 shares of Processa Pharmaceuticals at 0.198 subject to Rule 16b-3 | 01/21/2026 |
| Begin Period Cash Flow | 4.7 M | |
| Total Cashflows From Investing Activities | -3244.00 |
Processa Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 925.00 in Processa Pharmaceuticals on November 1, 2025 and sell it today you would lose (611.00) from holding Processa Pharmaceuticals or give up 66.05% of portfolio value over 90 days. Processa Pharmaceuticals is currently does not generate positive expected returns and assumes 18.8801% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Processa, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Processa Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Processa Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.14 | 90 days | 3.14 | about 87.51 |
Based on a normal probability distribution, the odds of Processa Pharmaceuticals to move above the current price in 90 days from now is about 87.51 (This Processa Pharmaceuticals probability density function shows the probability of Processa Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.57 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Processa Pharmaceuticals will likely underperform. Additionally Processa Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Processa Pharmaceuticals Price Density |
| Price |
Predictive Modules for Processa Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Processa Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Processa Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Processa Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Processa Pharmaceuticals is not an exception. The market had few large corrections towards the Processa Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Processa Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Processa Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.13 | |
β | Beta against Dow Jones | 1.57 | |
σ | Overall volatility | 2.19 | |
Ir | Information ratio | -0.0052 |
Processa Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Processa Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Processa Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Processa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Processa Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (11.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Processa Pharmaceuticals currently holds about 12.06 M in cash with (11.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Processa Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Pannu Geraldine of 300000 shares of Processa Pharmaceuticals at 0.198 subject to Rule 16b-3 |
Processa Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Processa Stock often depends not only on the future outlook of the current and potential Processa Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Processa Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 122.4 K | |
| Cash And Short Term Investments | 1.2 M |
Processa Pharmaceuticals Fundamentals Growth
Processa Stock prices reflect investors' perceptions of the future prospects and financial health of Processa Pharmaceuticals, and Processa Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Processa Stock performance.
| Return On Equity | -2.71 | ||||
| Return On Asset | -1.3 | ||||
| Current Valuation | 806.09 K | ||||
| Shares Outstanding | 2.27 M | ||||
| Price To Book | 1.22 X | ||||
| EBITDA | (12.05 M) | ||||
| Net Income | (11.85 M) | ||||
| Cash And Equivalents | 12.06 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 73.51 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.89 X | ||||
| Book Value Per Share | 2.76 X | ||||
| Cash Flow From Operations | (11.25 M) | ||||
| Earnings Per Share | (28.75) X | ||||
| Market Capitalization | 7.11 M | ||||
| Total Asset | 3.23 M | ||||
| Retained Earnings | (87.22 M) | ||||
| Working Capital | 340.99 K | ||||
About Processa Pharmaceuticals Performance
By analyzing Processa Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Processa Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Processa Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Processa Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 635.83 | 342.18 | |
| Return On Tangible Assets | (3.30) | (3.47) | |
| Return On Capital Employed | (8.17) | (7.76) | |
| Return On Assets | (3.30) | (3.47) | |
| Return On Equity | (8.03) | (7.63) |
Things to note about Processa Pharmaceuticals performance evaluation
Checking the ongoing alerts about Processa Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Processa Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Processa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Processa Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (11.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Processa Pharmaceuticals currently holds about 12.06 M in cash with (11.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Processa Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Pannu Geraldine of 300000 shares of Processa Pharmaceuticals at 0.198 subject to Rule 16b-3 |
- Analyzing Processa Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Processa Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Processa Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Processa Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Processa Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Processa Pharmaceuticals' stock. These opinions can provide insight into Processa Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |